Based on a unified board of 300 KR·US·JP stocks · updated July 16, 2026 at 02:07 AM KST
Eli Lilly and Company is 23.7× Samsung Biologics
As of July 16, 2026 at 02:07 AM KST, Eli Lilly and Company (LLY) has a market cap of $1.02T — #13 worldwide — while Samsung Biologics (207940.KS) stands at $43B, ranking #147. The gap is $977B; Samsung Biologics is 4.2% the size of Eli Lilly and Company.
Eli Lilly and Company ranks #12 among US stocks (Healthcare), and Samsung Biologics ranks #9 among Korea stocks (Healthcare).
If Samsung Biologics reached Eli Lilly and Company's market cap, its share price would need to go from $929.55 to $22041.20 (about +2271%).